Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation

Annals of the New York Academy of Sciences

Volumn 1095, Issue , 2007, Pages 154-164

  Petrovíc, Ivan M ^a   Korícanac, Lela B ^a   Todorovíc, Danijela V ^a   Ristíc Fira, Aleksandra M ^a   Valastro, Lucia M ^b   Privitera, Giuseppe ^c   Cuttone, Giacomo ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b INFN SEZIONE DI CATANIA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cell survival; Dacarbazine; Fotemustine; HTB140 melanoma cells; Proton irradiation; Viability

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALKYLATING AGENT; DACARBAZINE; FOTEMUSTINE; PROTON; SULFORHODAMINE B; ANTINEOPLASTIC AGENT; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

CANCER CELL; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL SURVIVAL; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EXPOSURE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MONOTHERAPY; PROTON RADIATION; RADIATION DOSE; SINGLE DRUG DOSE; ARTICLE; DRUG EFFECT; PATHOLOGY; RADIATION EXPOSURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; HUMANS; MELANOMA; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROTONS;

EID: 34247844384     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1397.019     Document Type: Conference Paper

References (22)

1. SOENGAS, M.S. & S.W. LOWE. 2003. Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151.
2. JUNGNELIUS, U., U. RINGBORG, S. AAMDAL, et al. 1998. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. Eur. J. Cancer 34: 1368-1374.
3. ILIADIS, A., M.C. LAUNAY-ILIADIS, C. LUCAS, et al. 1996. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French Cancer Centre multicentric study. Eur. J. Cancer 32A: 455-460.
4. GROSSMAN, D. & D.C. ALTIERI. 2001. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metas. Rev. 20: 3-11.
5. KINNAERT, E., R. MORANDINI, S. SIMON, et al. 2000. The degree of pigmentation modulates the radiosensitivity of human melanoma cells. Radiat. Res. 154: 497-502.
6. KRENGLI, M., J.E. MUNZENRIDER & H.D. SUIT. 1997. Clinical experience with proton beam therapy at MGH, MEEI and HCL: skull base sarcoma and uveal melanoma. In Advances in Hadrontherapy. U. Amaldi, B. Larsson & Y. Lemoigne, Eds.: 95-102. Elsevier. Amsterdam.
7. CHU, W.T., B. LUDEWIGT & T.R. RENNER. 1993. Instrumentation for treatment of cancer using proton and light-ions beams. Rev. Sci. Inst. 64: 2055-2122.
8. BELLI, M., D. BETTEGA, P. CALZOLARI, et al. 2000. Inactivation of human normal and tumour cells irradiated with low energy protons. Int. J. Radiat. Biol. 76: 831-839.
9. IAEA TECHNICAL REPORT SERIES N. 398. 2000. Absorbed dose determination in external beam radiotherapy: an international code of practice for dosimetry based on standards of absorbed dose to water. Pp. 135-150.
10. HOUGHTON, A.N., F.X. REAL, L.J. DAVIS, et al. 1987. Phenotypic heterogeneity of melanoma; relation to the differentiation program of melanoma cells. J. Exp. Med. 164: 812-829.
11. MITCHELL, M.S. 2004. Chemotherapy for melanoma: the resultant of conflicting vectors. J. Clin. Oncol. 22: 1-3.
12. SHIBUYA, H., Y. KATO, S. MASUYOSHI, et al. 2003. Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins. Melanoma Res. 13: 457-464.
13. MIYATO, Y. & K. ANDO. 2004. Apoptosis of human melanoma cells by a combination of lonidamine and radiation. J. Radiat. Res. 45: 189-194.
14. RÜNGER, T.M., S. EMMERT, D. SCHADENDORF, et al. 2000. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine or etoposide. J. Invest. Dermatol. 114: 34-39.
15. MEULENANS, A., B. GIROUX, P. HANNOUN, et al. 1989. Permeability of two nitrosoureas, carmustine and fotemustine in rat cortex. Chemotherapy 35: 313-319.
16. WINUM, J.Y., J.L. BOUISSIERE & I. PASSAGNE. 2003. Synthesis and biological evaluation of fotemustine analogues on human melanoma cell line. Eur. J. Med. Chem. 38: 319-324.
17. SANADA, M., Y. TAKAGI, R. ITO & M. SEKIGUCHI. 2004. Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations. DNA Repair 3: 413-420.
18. ALLEY, M.C., D.A. SCUDIERO, A. MONKS, et al. 1988. Feasibility of drug screening with panels of human tumor cell lines using a microculture tertazolium assay. Cancer Res. 48: 589-601.
19. PRICE, P. & T.J. MCMILLAN. 1990. Use of the tetrazolium assay in measuring the response of human tumor cells to ionizing radiation. Cancer Res. 50: 1392-1396.
20. RUBINSTEIN, L.V., R.H. SHOEMAKER, K.D. PAULL, et al. 1990. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82: 1113-1118.
21. MARSHALL, E.S., J.H.L. MATTHEWS, J.H.F. SHAW, et al. 1994. Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays. Eur. J. Cancer 30A: 1370-1376.
22. KINNAERT, E., P. DUEZ, R. MORANDINI, et al. 2004. Cysteine but not glutathione modulates the radiosensitivity of human melanoma cells by affecting both survival and DNA damage. Pigment Cell Res. 17: 275-280.